Brief Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dosethe amount of medication taken (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Intervention / Treatment
- Drug: KLN-1010
Inclusion Criteria:
- Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease.
- Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directed monoclonal antibodya protein made by the immune system to fight against harmful substances (antigens), such as bacteria or viruses.
- Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1.
- Participants must have acceptable laboratory values as defined by the protocol.